SpotLight™
A 30-second, non-invasive optical biosignature screening platform. Real-time biological insights across multiple indications.
SpotLight-C™Cancer Screening
SpotLight-C™ is under development for non-invasive early-stage cancer detection and real-time chemotherapy response monitoring.
Selected for the 2026 Mayo Clinic & ASU Health Care Accelerator.
SpotLight-19™Pathogen Detection
SpotLight-19™ was developed during the COVID-19 pandemic and is being expanded to include a range of pathogens, without the need for a biological sample. A 30-second, non-invasive screening test designed for rapid, scalable deployment at point of care.
Invited as participant in the National Security Commission on Emerging Biotechnology Arizona Summit.
The SpotLight™ platform is approaching biosensing differently.
-
Non-invasive
SpotLight™ is a truly non-invasive screening experience, unlike current invasive methods that require a sample of blood, urine, saliva, stool or tissue.
-
Expandable Platform
SpotLight™ has the ability to respond to emerging health challenges with timely and seamless algorithm uploads without the need for hardware modifications.
-
Environmentally Friendly
SpotLight™ eliminates hazardous chemical reagent waste and the environmental and health risks associated with current health monitoring methods.
-
Real-time Health Data
SpotLight™ provides immediate results, versus the days or weeks required for private clinics to have blood or stool samples processed by domestic or off-shore labs.
-
No Expiry Date
SpotLight™ avoids the cost and logistical challenges arising from the expiry of chemical reagent-based tests, as observed during the COVID-19 pandemic.
-
Low Cost Per Test
SpotLight™ offers low-cost screening, providing financial relief to overwhelmed inner city healthcare systems and under-staffed rural healthcare systems.